Thrombomodulin (TM), also known as CD141, is an integral membrane protein expressed on the surface of endothelial cells. It functions as a cofactor in the thrombin-induced activation of protein C by forming a 1:1 complex with thrombin. This complex stimulates fibrinolysis by cleaving thrombin-activatable fibrinolysis inhibitor (TAFI) into its active form. Increased serum levels of thrombomodulin have been associated with smoking, cardiac surgery, atherosclerosis, liver cirrhosis, diabetes mellitus, cerebral and myocardial infarction, and multiple sclerosis.
Swiss-Prot Accession Number: P07204
Publications Biomarker panels associated with progression of renal disease in type 1 diabetes.
(2019) Colombo M, Valo E, McGurnaghan SJ, Sandholm N, Blackbourn LAK, Dalton RN, Dunger D, Groop PH, McKeigue PM, Forsblom C, Colhoun HM Diabetologia
Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation
(2019) Levitsky J, Asrani SK, Klintmalm G, Schiano T, Moss A, Chavin K, Miller C, Guo K, Zhao L, Jennings LW, Brown M, Armstrong B, Abecassis M Hepatology
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment
(2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Complexity of Macrophage Migration Inhibitory Factor (MIF) and Other Angiogenic Biomarkers Profiling in Pulmonary Arterial Hypertension.
(2017) Marshall JD, Sauler M, Tonelli A, Rao Y, Bucala R, Lee P, Fares W Pulm Circ.
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests
(2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports